Moreover, across the four patient groups, MALAT1 expression levels in pre-osteoclasts and osteoclasts were significantly lower in patients with osteoporosis, osteosarcoma, or breast cancer bone metastasis than in the non-osteoporotic individual (Fig. 4i–k). Here, MALAT1 is linked to breast cancer.